Diabetes Mellitus Clinical Trial
Official title:
Effects of Standardized Meals With Different Compositions of Fat, Protein and Carbohydrate on the Metabolic, Hormonal and Inflammatory Responses in Human
| NCT number | NCT02544568 |
| Other study ID # | 2007/801-32 |
| Secondary ID | |
| Status | Completed |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | November 2009 |
| Est. completion date | February 2016 |
| Verified date | March 2019 |
| Source | Karolinska University Hospital |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Meal composition is important for blood sugar levels in patients with diabetes. The aim of
this study is to investigate if a meal composition of fat, protein and carbohydrate is
important for the hormonal and inflammatory responses Patients with type 1 and type 2
diabetes and healthy controls will be included in the study. At four different occasions the
participants will receive lunch with the same amount of calories but different composition of
fat, protein, carbohydrate and fiber. Blood samples will be taken before and after the meals.
The participants will estimate their satiety. In addition participant will fill in
questionnaires about their food habits and wellbeing.
This study is the first study to compare both hormonal and inflammatory responses, as well as
psychological aspect of the meals, after meals with different composition. Results from this
study will help to make recommendation about meal composition which is beneficial for
patients with diabetes type 1 and type 2.
| Status | Completed |
| Enrollment | 68 |
| Est. completion date | February 2016 |
| Est. primary completion date | February 2016 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 20 Years to 75 Years |
| Eligibility |
Inclusion Criteria: - Patient with type 1 DM (age 20-75 years) - Patient with type 2 DM (diabetes duration more than 5 years, age 20- 75 years, BMI 26 - 33 kg/m2). - Healthy volunteers (age 20- 75 years). Exclusion Criteria: - Heart failure - the New York Heart Association (NYHA) Functional Classification III-IV - Kidney failure - S-Creatinin mora than 200 micromol/L - Liver disease - Alanine aminotransferase (ALAT) more than 2 mikroKat/L |
| Country | Name | City | State |
|---|---|---|---|
| Sweden | Karolinska University Hospital | Stockholm |
| Lead Sponsor | Collaborator |
|---|---|
| Karolinska University Hospital |
Sweden,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Maximum plasma concentration [Cmax] of glucose and triglycerides | The maximum plasma concentration of glucose and triglyceres after the meals | 1 year | |
| Secondary | Maximum plasma concentration [Cmax] of IGFBP-1 | The maximum plasma concentration of IGFBP-1 after the meals | 2 year | |
| Secondary | Maximum plasma concentration [Cmax] of marker of oxidative stress | The maximum plasma concentration of markers of oxidative stress after the meals | 2 year | |
| Secondary | Maximum plasma concentration [Cmax] of inflammatory markers | The maximum plasma concentration of inflammatory markers after the meals | 2 year | |
| Secondary | Maximum plasma concentration [Cmax] of appetite regulatory hormones | The maximum plasma concentration of apetite regulatory hormones after the meals | 2 years | |
| Secondary | Maximum plasma concentration [Cmax] of glucagon | The maximum plasma concentration of glucagon after the meals | 2 years |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
| Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
| Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
| Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
| Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
| Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
| Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
| Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
| Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
| Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
| Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
| Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
| Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
| Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
| Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
| Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |